{"entity":{"id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","aka":[],"tldr":"A phase 2 trial of Albipagrastim alf in childhood cancers, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","summary":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants is a phase 2 interventional study registered as NCT07724756 by Qilu Pharmaceutical Co., Ltd., with 18 participants planned, started 2026-06-26 and due to reach its primary completion in 2027-06-26. Interventions recorded: Albipagrastim alf.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07724756","url":"https://clinicaltrials.gov/study/NCT07724756"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07724756","phase":"2","setting":"A Multicenter, Open-label Phase II Clinical Study Evaluating the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Albipagrastim Alfa for Injection (QLC2519) in Pediatric Solid Tumor Participants","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrolled":18,"outcomes":[]},"route":"/trials/nct07724756/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}]}}